Please assess the completion status of the following clinical trial:

Trial Title: Multi-Centre Trial of Fresh vs. Frozen-and-Thawed FMT for Recurrent CDI

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Patient inclusion criteria~1. Age 18 years or older.~2. Able to provide informed consent.~3. Laboratory or pathology: confirmed diagnosis of recurrent CDI with symptoms (defined below) within the previous 180 days.~4. ≥ 2 episodes of CDI within 6 months and/or ongoing symptoms consistent with CDI despite treatment with oral vancomycin at a dose of at least 125 mg 4 times daily for at least 5 days.~Symptoms of CDI, diarrhea deﬁned as: 3 or more unformed bowel movements in 24 hours for a minimum of 2 days with no other causes for diarrhea. Subjects will be required to have laboratory or pathology-confirmed diagnosis of recurrent C. difficile infection where recurrence is deﬁned as return of diarrhea and positive stool test after a period of symptom resolution within 8 weeks of the first episode and has received at least a 10-day course of standard antibiotic therapy.~Patient exclusion criteria~1. Planned or actively participating in another clinical trial.~2. Patients with neutropenia with absolute neutrophil count \<0.5 x 109/L~3. Evidence of toxic megacolon or gastrointestinal perforation on abdominal x-ray~4. Peripheral white blood cell count \> 30.0 x 10E9/L AND temperature \> 38.0 oC~5. Active gastroenteritis due to Salmonella, Shigella, E. coli 0157H7, Yersinia or Campylobacter.~6. Presence of colostomy~7. Unable to tolerate HBT or enema for any reason.~8. Requiring systemic antibiotic therapy for more than 7 days.~9. Actively taking Saccharomyces boulardii~10. Severe underlying disease such that the patient is not expected to survive for at least 30 days.~11. Any condition that, in the opinion of the investigator, that the treatment may pose a health risk to the subject.~Donor inclusion~1. Able to provide and sign informed consent.~2. Able to complete and sign the donor questionnaire~3. Able to adhere to fecal transplantation stool collection standard operating procedure.~Donor exclusion~1. Tested positive for any of the following: Human Immunodeficiency virus (HIV) 1/2, hepatitis IgM, hepatitis B (HBsAg), hepatitis C antibody, syphilis, human T- lymphotrophic virus (HTLV) 1/II and vancomycin resistant Enterococcus (VRE), methicillin resistant S. aureus (MRSA), Salmonella, Shigella, E.coli O157 H7, Yersinia and Campylobacter.~2. Detection of ova, parasites, C. difficile toxin, norovirus, adenovirus, rotavirus on stool examination~3. History of any type of active cancer or autoimmune disease~4. History of risk factors for acquisition of HIV, syphilis, Hepatitis B, Hepatitis C, prion or any neurological disease as determined by the donor questionnaire, appendix B.~5. History of gastrointestinal comorbidities, e.g., inflammatory bowel disease, irritable bowel syndrome, chronic constipation or diarrhea~6. Receipt of blood transfusion from a country other than Canada in preceding 6 months~7. Antibiotic use or any systemic immunosuppressive agents in the 3 months prior to stool donation~8. Receipt of any type of live vaccine within 3 months prior to stool donation~9. Ingestion of nut or shell fish 3 days preceding donation if the recipient has known allergies to these food.~10. Any current or previous medical or psychosocial condition or behaviours which in the opinion of the investigator may pose risk to the recipients or the donor

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Fresh FMT (Type: EXPERIMENTAL): Participants in this arm will receive Fresh FMT via rectal administration. They will be followed for 13 weeks to assess the cure or recurrence of CDI. All other procedures between the two arms will be identical.
- Frozen-and-Thawed FMT (Type: EXPERIMENTAL): Participants in this arm will receive Frozen-and-Thawed FMT via rectal administration. They will be followed 13 weeks to assess the cure or recurrence of CDI. All other procedures between the two arms will be identical.

Based on this trial design, predict the completion outcome and termination type (if applicable).